Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | PARP1 | P09874 | 2/20 | 0.47 |
| ▸ | AURKA | O14965 | 2/20 | 0.47 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | PAK4 | O96013 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29416439 | 1.00 | PDE4A (0.52) | PDE4APDE4BPDE4CPDE4DNR4A2 | |
| SCHEMBL8974755 | 0.79 | NR4A2 (0.47) | PDE4APDE4BPDE4CPDE4DNR4A2 | |
| SCHEMBL3763540 | 0.79 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DSMN1; SMN2 | |
| SCHEMBL29460991 | 0.79 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DSMN1; SMN2 | |
| SCHEMBL856383 | 0.79 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DSMN1; SMN2 | |
| SCHEMBL10292146 | 0.79 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DNR4A2 | |
| SCHEMBL856304 | 0.79 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DSMN1; SMN2 | |
| SCHEMBL4510131 | 0.79 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DSMN1; SMN2 | |
| SCHEMBL13783328 | 0.79 | NR4A2 (0.47) | NR4A2SMN1; SMN2PARP1AURKADAPK3 | |
| SCHEMBL12069917 | 0.79 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DNR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | PLIANT THERAPEUTICS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2025-07-10 | — | — | US | disclosed |
| EP-4520329-A2 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | Pliant Therapeutics, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4509512-A2 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| EP-4329755-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | Pliant Therapeutics, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| EP-4328230-A2 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| CN-117615760-A | Extended dosage regimen for integrin inhibitors | 普利安特治疗公司 | 2024-02-27 | — | — | CN | disclosed |
| EP-3761980-B1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS INC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230271960-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS INC (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230181546-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | PLIANT THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20100184786-A1 | Polar Quinazolines | WYETH LLC (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2010059627-A1 | POLAR QUINAZOLINES AS LIVER X RECEPTORS ( LXRS ) MODULATORS | WYETH LLC (US) | 2010-05-27 | — | — | WO | disclosed |
| EP-2142517-A2 | QUINAZOLINE COMPOUNDS | Wyeth (US) | 2010-01-13 | — | — | EP | disclosed |
| WO-2009020683-A2 | QUINAZOLINE COMPOUNDS | WYETH (US) | 2009-02-12 | — | — | WO | disclosed |
| US-5736534-A | HYPERPROLIFERATIVE DISEASES; INHIBITORS OF PROTEIN-TYROSINE KINASES SUCH AS EPIDERMAL GROWTH FACTOR RECEPTOR; BRAIN, LUNG, BREAST CANCER; PSORIASIS AND BENIGN PROSTATE HYPERPLASIA | PFIZER INC. (US) | 1998-04-07 | — | — | US | disclosed |
| EP-0746554-A1 | 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | PFIZER INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| EP-0606024-B1 | Erythromycin derivatives, their process of preparation and their application as medicaments | ROUSSEL UCLAF (FR) | 1996-03-20 | — | — | EP | disclosed |
| WO-1995023141-A1 | 4-HETEROCYCLYL-SUBSTITUTED QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | PFIZER INC. (US) | 1995-08-31 | — | — | WO | disclosed |
| US-4464375-A | ANALGESIC, ANTIINFLAMMATORY | SANKYO CO., LTD. (JP) | 1984-08-07 | — | — | US | disclosed |
| US-4322420-A | Method of using 4-anilinoquinazoline derivatives as analgesic and anti-inflammatory agents | SANKYO COMPANY LIMITED (JP) | 1982-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271960-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | PDE4A 3921/4885PDE4B 3861/4885PDE4C 4299/4885 |
| US-20100184786-A1 | Polar Quinazolines | NR1H3, NR1H2, NR1I3 | PDE4A 1300/4885PDE4B 1099/4885PDE4C 2183/4885 |
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | ITGB6, ITGA6, ITGAV | PDE4A 3891/4885PDE4B 3849/4885PDE4C 4382/4885 |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | PDE4A 3921/4885PDE4B 3861/4885PDE4C 4299/4885 |
| US-20230181546-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | ITGA5, ITGAL, ITGB5 | PDE4A 4310/4885PDE4B 4312/4885PDE4C 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.